Medical News Bulletin - Daily Medical News, Health News, Clinical Trials And Clinical Research, Medical Technology, Fitness And Nutrition News–In One Place

Apparently, somewhere, somebody has been claiming that neonatal male circumcision causes autism spectrum disorder. Rather than immediately dismissing this unusual idea, a team of paediatricians and epidemiologists based in the USA tested the hypothesis thoroughly and found it easy to disprove. They published the results of the study in JAMA Pediatrics, a well respected medical […]

The post Bulletin: Circumcision Doesn’t Cause Autism appeared first on Medical News Bulletin.

Medical News Bulletin - Daily Medical News, Health News, Clinical Trials And Clinical Research, Medical Technology, Fitness And Nutrition News–In One Place

Wheelchair assessment involves much more than body dimensions and mobility needs. Factors such as daily activities, occupational requirements, transport, and domestic environment have to be considered when assessing the performance of a wheelchair after delivery. Ignoring such factors will end up delivering a wheelchair that is less efficient in its use because of lifestyle changes. […]

The post Seven Lifestyle Details Users Must Share During a Wheelchair Assessment appeared first on Medical News Bulletin.

Medical News Bulletin - Daily Medical News, Health News, Clinical Trials And Clinical Research, Medical Technology, Fitness And Nutrition News–In One Place

New treatments are being added to the traditional therapies of surgery, chemotherapy and radiation therapy for patients with esophageal cancer. These include advances in the use of molecular testing and in the concept of multidisciplinary care of patients with this disease. This article outlines the latest development in the treatment and management of patients with […]

The post Recent Advances in Esophageal Cancer Treatment: What the Latest Research Shows appeared first on Medical News Bulletin.

The Ebola virus outbreak that has killed more than 1,800 people in the Democratic Republic of the Congo is now the second-largest Ebola outbreak on record.
The case count has surpassed 4,000 and includes at least 1,852 deaths, according to the CDC, which warned that the virus is “spreading substantially faster” than any previous Ebola outbreak.
Several factors, including insecurity in the region, are complicating the response, officials have said. Additionally, there are no licensed vaccines or treatments for the rare species of Ebola virus, Bundibugyo ebolavirus, that is causing

The FDA has approved oveporexton for the treatment of narcolepsy type 1 in adults, according to officials with Takeda, the drug’s developer.
Oveporexton (Orzeyful, Takeda), an oral orexin receptor 2 agonist, is the first medicine indicated in the U.S. to treat narcolepsy type 1 (NT1) holistically instead of treating individual symptoms, Takeda officials said in a press release.
“Until now, people have managed narcolepsy type 1 with treatments that target symptom relief,” Emmanuel Mignot, MD, PhD, Craig Reynolds Professor of Sleep Medicine at Stanford University, said in a statement.
“As the

A pivotal trial is now underway for i-Lumen AMD, a bioelectric therapy being investigated for intermediate to advanced dry age-related macular degeneration, according to a press release from i-Lumen Scientific.
The noninvasive, office-based therapy applies low-level microcurrent stimulation via the closed eyelid, which may improve photoreceptor cell function by repolarizing retinal pigment epithelium cells, according to the company.
Each treatment session lasts about 30 minutes for one eye and 45 minutes for both eyes, John VeLure, CEO at i-Lumen Scientific, told Healio.
“Participants,

Serial assessments for neurodevelopmental disorders should take place earlier and more often for people with sickle cell disease, according to new standards and recommendations released by the National Alliance of Sickle Cell Centers.
The new guidelines are needed in part because current national guidelines do not offer enough clarity for how SCD centers should best identify and navigate cognitive risks, said Alyssa Schlenz, PhD, associate professor of pediatrics with Children’s Hospital Colorado.
“If you’re a patient with sickle cell disease and you receive care in one state, that care can

Clesrovimab was well-tolerated among children entering their second respiratory disease season, according to the latest results from the phase 3 SMART trial.
The findings indicate that the long-acting monoclonal antibody (mAb) could be another option to protect kids against respiratory syncytial virus in their second season.
“Respiratory syncytial virus is one of the most common causes of acute lower respiratory infection and hospitalization among infants worldwide, leading to a substantial number of infant deaths annually, most occurring in low- and middle-income countries,” Heather J. Zar,

The FDA has granted accelerated approval to vusolimogene oderparepvec-wtpg in combination with nivolumab for adults with unresectable advanced cutaneous melanoma who experienced disease progression with a prior anti-PD-1 therapy.
The approval for vusolimogene oderparepvec-wtpg (Tudriqev, Replimune) — an oncolytic immunotherapy previously called RP1 — comes after two prior rejections within the last 13 months, with the FDA previously citing concerns with both the submitted trial design and evidence of effectiveness.
“For patients with advanced melanoma that has stopped responding to PD-1

Xylazine scheduling may have contributed to a substantial increase in medetomidine in the U.S. illicit drug supply, a new research paper suggests.
“Although this study is the first to examine this for xylazine/medetomidine, these ‘iron law of prohibition’ patterns are not new,” David T. Zhu, an MD/PhD candidate at Virginia Commonwealth University, told Healio. “Currently, many state policymakers and legislators are still debating whether to schedule xylazine and medetomidine — our findings provide a cautionary tale against these supply-side drug control policies.”
In recent years, there has